Latest Breaking News On - Pneumococcal diseases - Page 1 : comparemela.com

Merck s adult-specific pneumococcal vaccine shows promise in late-stage study

Merck s adult-specific pneumococcal vaccine shows promise in late-stage study
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Eliav barrMeeting of the international society pneumoniaMerck coMerck research laboratoriesEuropean society of clinical microbiologyWorld health organizationWorld healthEuropean societyClinical microbiologyInfectious diseasesInternational societyPneumococcal diseases

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases Results build on the data supporting the clinical profile.

United statesComunidad autonoma de catalunaEliav barrWalter orensteinEmory universityMeeting of the international society pneumoniaStatement of merck co incEuropean medicines agencyWorld vaccine congress west coastExchange commissionMerck research laboratoriesMerck scientific advisory committeeUs centers for diseaseEuropean society of clinical microbiologyMerck co incDrug administration

Merck (MRK) Q1 2024 Earnings Call Transcript

MRK earnings call for the period ending March 31, 2024.

United statesLuisa hector berenbergDaiichi sankyo adcsSeamus fernandezAsia pacificJames shinLouise chenLouise chen cantor fitzgeraldEvan seigermanPeter dannenbaumRob davisDaina graybosch leerinkChris schott jpmorganTim andersonCarter gould barclaysLuisa hector

Merck (MRK) Q1 2024 Earnings Call Transcript

MRK earnings call for the period ending March 31, 2024.

United statesChris schottSeamus fernandezJames shinCarter gouldSeamus fernandez guggenheimTerence flynn morgan stanleyDaina grayboschChris shibutani goldman sachsChris schott jpmorganTerence flynnCaroline litchfieldLuisa hectorCarter gould barclaysRob davisTrung huynh

Merck s V116 Vaccine Shows Promising Results in Phase 3 Studies at ISPPD: Key Findings and Real-World Impact

Merck's V116, a 21-valent pneumococcal vaccine, exhibits strong immunogenicity and coverage in diverse adult populations. Real-world data reveal its potential to combat pneumococcal diseases effectively.

South africaCape townWestern capeHeather plattMerck heather plattMeeting of the international society pneumoniaGlobal clinical development for vaccinesInfection intelStaying aheadInfection controlInternational societyPneumococcal diseasesPrescription drug user fee actPneumococcal pneumonia epidemiologyUrine serotypingMental outcomes